semaglutide trial adolescents obesity 2022 SELECT Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months Category:Strobe Lights Program:Monthly Dual and Triple Gut

semaglutide trial adolescents obesity 2022 SELECT Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months Category:Strobe Lights Program:Monthly Dual and Triple Gut

Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data - PMC

complements a balanced, active lifestyle instead of replacing it, no crash diets or extreme changes required

Category:Strobe Lights

Program:Monthly

Coverage may require prior authorization, typically for patients with a BMI of 30 and above or 27 with weight-related conditions